Health
CSOFT’s health blog aims to provide insight into complex diseases, treatment options and regulatory developments, and other prevalent health issues people face today.
ChatGPT in Healthcare: A Tool to Improve Patient Communication and Medical Translations?
Since OpenAI publicly released ChatGPT, a generative artificial intelligence (AI) that uses a large language model to produce human-like text, the possibilities for ChatGPT have taken just about every communication and translation-heavy industry by storm. But in the...
ePRO Translations: Cultural Adaptation for the Decentralized Clinical Trial
Patient-reported outcome (PRO) translations have long required linguistic validation before use in clinical trials, so with the rise of digital instruments in decentralized clinical trials, what additional considerations are there for electronic PRO (ePRO)...
eLearning Translations: Improving Medical Device Use Around the Globe
How can medical device companies leverage eLearning translations to improve the use of medical devices around the world? While patients are the end user for many medical devices, healthcare professionals are responsible for guiding patients in correct use, as well as...
Clinical Trial Corner: Quantifying the Socioeconomic Value of Industry Clinical Trials for Participating Countries
Clinical Trial Corner is a biweekly series from Dr. Vladimir Misik, founder of LongTaal and CSOFT’s VP of Global Clinical Strategy. In our previous CT Corner posts we assessed patient diversity on a global scale and flagged countries and regions that appear to be...
Patient Recruitment Translations: A Treatment for the Reputation Disparity in Clinical Trials?
How can patient-facing materials and patient recruitment translations facilitate recruitment of patients particularly to countries underrepresented in global drug development? As we discussed in our latest Clinical Trial Corner post, some countries and regions,...
Clinical Trial Corner: Assessment of Countries’ Reputation Among Sponsors of Industry Clinical Trials
Clinical Trial Corner is a biweekly series from Dr. Vladimir Misik, founder of LongTaal and CSOFT’s VP of Global Clinical Strategy. In the previous two-part Clinical Trial Corner miniseries, we provided a global assessment of patient diversity in industry CTs (iCTs)...
Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022
Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a leading neuroscience-focused biopharmaceutical company, reported additional results from the Phase 3 KINECT-HD study investigating valbenazine for the treatment of chorea associated with Huntington Disease (HD). In...
AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development
AbCellera (Nasdaq: ABCL) announced that Regeneron has elected to exercise its right to advance a therapeutic antibody candidate, discovered in partnership with AbCellera as part of a multi-target collaboration between the companies, into further preclinical...
Unity Bio Set to Launch Pivotal DME Study after Significant Data
Shares of Unity Biotechnology surged in early trading Tuesday following the company’s release of Phase II data showing a single injection of its experimental drug provided visual improvements in patients with diabetic macular edema. A single injection of UBX1325 led...
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, announced that the U.S. Food and Drug Administration (FDA) has granted...
Categories
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com